An early arrival among '17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play
AnaptysBio has upped its shares but still managed to hit the mid-point of its IPO range, raising $75 million.
The successful outing marks an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
